Investigating the long-term impact of nicotine replacement products on tobacco smoking cessation for low-socioeconomic status smokers

Participants of ACTRN12621000076875 were allocated a specific nicotine replacement product (vaporised nicotine product or oral nicotine replacement therapy [nicotine gum or lozenge]) at baseline. This observational extended follow-up study investigates participants that successfully quit smoking (met trial primary outcome) in ACTRN12621000076875. Participants will be invited to take part/consent to the long-term follow-up study after their participation in ACTRN12621000076875 is complete (eg. 7-month interview and breath test completed). This follow-up study involves a 15 minute telephone interview with a member of the research team at 19-months post baseline interview for ACTRN12621000076875. All participants will be asked to provide a salivary sample (collection kits sent and received via registered post) for analysis for presence of cotinine. The analysis will be completed by an independent laboratory in New South Wales, Australia. Participants that meet the self-reported abstinence outcome of less than or equal to 5 cigarettes in the 12-month period since their last interview (at the 19-month interview) will be asked to complete a carbon monoxide breath test. The breath test can be completed in-person or over a video call with a member of the research team.